Table 2.
The indirect comparison of selected studies based on the mirror principle.
| Matched groups | RCT name | Immunotherapy drug | Therapeutic schedule | Clinical trial Phase | Therapeutic schedule | Lines of Treatment | PD-L1 status | ECOG-PS | Male (%) ± 2% |
|---|---|---|---|---|---|---|---|---|---|
| 1 | KEYNOTE-045 | PD-L1 | Pembrolizumab | III | Platinum-based chemotherapy | ≤3 | All | 0–1** | 72% (+2%) |
| IMvigor211 | PD-1 | Atezolizumab | III | Platinum-based chemotherapy | ≤3 | All | 0–1 | 72% (−2%) | |
| 2 | CheckMate 275 | PD-L1 | Nivolumab | II | Platinum-based chemotherapy | 2 | All | 0–1*** | 78% (0) |
| IMvigor210 (Cohort 2) | PD-1 | Atezolizumab | II | Platinum-based chemotherapy | 2 | All | 0–1 | 78% (0) | |
| 3 | CheckMate 032 | PD-L1 | Nivolumab | I/II | Platinum-based chemotherapy | 2 | All | 0–1 | 70% (−1%) |
| Study 1108 | PD-1 | Durvalumab | I/II | Platinum-based chemotherapy | 2 | All | 0–1 | 70% (+1%) | |
| 4 | KEYNOTE-012 | PD-L1 | Pembrolizumab | Ib | Previous treatment, including platinum-based therapy | ≥1 | ≥1% PD-L1 expression | 0–1 | 69% (+1%) |
| JAVELIN Solid (dose-expansion cohort) | PD-1 | Avelumab | Ib | Platinum-based chemotherapy | ≥1 | ≥1% PD-L1 expression* | 0-1 | 69% (-1%) |
*90% patients with ≥1% PD-L1 expression; **only 2 (0.7%) patients with ECOG performance status of 2; ***only one (0.4%) patient had ECOGperformance status of 3.